Blogs
October 25, 2023
Cell therapy weekly: Yescarta® becomes the first CAR-T therapy approved in China
This week: the China National Medical Products Administration has approved Yescarta® as the first CAR-T therapy in the country, the […]
Read more
October 10, 2023
Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma
Glioblastoma (GBM) is the most common malignant primary brain cancer in adults. It is always resistant to existing treatments, including […]
Read more
October 10, 2023
Three cases of late-onset post CAR-T therapy isolated CNS relapse in R/R large B-cell lymphoma
CD19-chimeric antigen receptor T-cell (CAR T-cell) therapy has improved the outcomes of relapsed/refractory large B cell lymphoma significantly. However, about […]
Read more
August 31, 2023
The improvement of CAR-T cells for glioblastoma
Read more
August 31, 2023
New CAR-T Technology in Solid Tumors From China
Read more
August 31, 2023
Penn researchers find a way through the labyrinth keeping CAR-T from solid tumors
Read more
August 31, 2023
CAR-T breakthrough therapeutic drugs CNCT19
Read more
August 31, 2023
Professor Zhang Yonghong: CAR-T cell therapy is fully attacked in hematological tumors and solid tum
Read more
August 31, 2023
Chinese scientists make T cells to enhance anti-tumor ability
Read more
August 31, 2023
Your Microbiome and Cancer: What to Know
Read more
